Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK1 receptor antagonists: Synthesis, antagonistic activity, and effects on bladder functions

Journal of Medicinal Chemistry

Volumn 42, Issue 19, 1999, Pages 3982-3993

  Natsugari, Hideaki ^a   Ikeura, Yoshinori ^a   Kamo, Izumi ^a   Ishimaru, Takenori ^a   Ishichi, Yuji ^a   Fujishima, Akira ^a   Tanaka, Toshimasa ^a   Kasahara, Fumiko ^a   Kawada, Mitsuru ^a   Doi, Takayuki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 7,8,9,10 TETRAHYDRO 9 METHYL 5 (4 METHYLPHENYL)[1,4]DIAZEPINO[2,1 G][1,7]NAPHTHYRIDINE 6,12 DIONE; 7 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 8,9,10,11 TETRAHYDRO 9 METHYL 5 (4 METHYLPHENYL) 7H [1,4]DIAZOCINO[2,1 G][1,7]NAPHTHYRIDINE 6,13 DIONE; BOLTON HUNTER REAGENT I 125; CAPSAICIN; DIMETHYL SULFOXIDE; EVANS BLUE; NAPHTHYRIDINE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ A; OXYBUTYNIN; SODIUM CHLORIDE; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER DISTENSION; BLADDER DYSFUNCTION; CHIRALITY; CONTROLLED STUDY; CYCLIZATION; DIASTEREOISOMER; DRUG EFFECT; DRUG SYNTHESIS; GUINEA PIG; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; POLLAKISURIA; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; URINE INCONTINENCE; X RAY ANALYSIS;

ANIMALS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; GUINEA PIGS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; MODELS, MOLECULAR; MUSCLE CONTRACTION; NAPHTHYRIDINES; PROTEIN CONFORMATION; RECEPTORS, NEUROKININ-1; URINARY BLADDER;

EID: 0033598446     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990220r     Document Type: Article

References (56)

1. Review articles: (a) Otsuka, M.; Yoshioka, K. Neurotransmitter Functions of Mammalian Tachykinins. Physiol. Rev. 1993, 73, 229-308.
2. (b) Maggi, C. A.; Patacchini, R.; Rovero, P.; Giachetti, A. Tachykinin Receptors and Tachykinin Receptor Antagonists. J. Auton. Pharmacol. 1993, 13, 23-93.
3. (c) Regoli, D.; Boudon, A.; Fauchere, J.-L. Receptors and Antagonists for Substance P and Related Peptides. Pharmacol. Rev. 1994, 46, 551-599.
4. 1 Tachykinin Receptor. Med. Res. Rev. 1996, 16, 297-317.
5. (e) Lowe, J. A., III. Nonpeptide Tachykinin Antagonists: Medicinal Chemistry and Molecular Biology. Med. Res. Rev. 1996, 16, 527-545.
6. 1) Receptor. Science 1991, 251, 435-437.
7. (b) McLean, S.; Ganong, A. H.; Seeger, T. F.; Bryce, D. K.; Pratt, K. G.; Reynolds, L. S.; Siok, C. J.; Lowe, J. A., III; Heym, J. Activity and Distribution of Binding Sites in Brain of a Nonpeptide Substance P (NK1) Receptor Antagonist. Science 1991, 251, 437-439.
8. (c) Lowe, J. A., III; Drozda, S. E.; Snider, R. M.; Longo, K. P.; Zorn, S. H.; Morrone, J.; Jackson, E. R.; McLean, S.; Bryce, D. K.; Bordner, J.; Nagahisa, A.; Kanai, Y.; Suga, O.; Tsuchiya, M. The Discovery of (2S, 3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan- 3-amine as a Novel, Nonpeptide Substance P Antagonist. J. Med. Chem. 1992, 35, 2591-2600.
9. 1 Receptor Antagonist. Eur. J. Pharmacol. 1993, 250, 403-413.
10. 1 Receptors. Neuropharmacology 1994, 33, 167-179.
11. 1 Antagonists: The Triarylperhydroisoindolols. Bioorg. Med. Chem. Lett. 1994, 4, 673-676.
12. 1 Receptor. Neuropeptides 1994, 26 (Suppl. 1), 34.
13. 1 Receptor. Neuropeptides 1994, 26 (Suppl. 1), 35.
14. (a) Desai, M. C.; Lefkowitz, S. L.; Thadeio, P. F.; Longo, K. P.; Snider, R. M. Discovery of a Potent Substance P Antagonist: Recognition of the Key Molecular Determinant. J. Med. Chem. 1992, 35, 4911-4913.
15. (b) McLean, S.; Ganong, A.; Seymour, P. A.; Snider, R. M.; Desai, M. C.; Rosen, T.; Bryce, D. K.; Longo, K. P.; Reynolds, L. S.; Robinson, G.; Schmidt, A. W.; Siok, C.; Heym, J. Pharmacology of CP-99,994; a Nonpeptide Antagonist of the Tachykinin Neurokinin-1 Receptor. J. Pharmacol. Exp. Ther. 1993, 267, 472-479.
16. (c) Desai, M. C.; Vincent, L. A.; Rizzi, J. P. Importance of Parallel Vectors and "Hydrophobic Collapse" of Aligned Aromatic Rings: Discovery of a Potent Substance P Antagonist. J. Med. Chem. 1994, 37, 4263-4266.
17. 1 Receptor. J. Pharmacol. Exp. Ther. 1996, 277, 900-908.
18. 1 Receptor Antagonist: Behavioural Effects. Neuropeptides 1994, 26 (Suppl. 1), 38;
19. 1 Antagonist. Bioorg. Med. Chem. Lett. 1996, 6, 1623-1628.
20. 1 receptor, and potent broad-spectrum anti-emetic activity. Regul. Pept. 1996, 65, 45-53.
21. (b) Armour, D. R.; Chung, K. M. L.; Congreve, M.; Evans, B.; Guntrip, S.; Hubbard, T.; Kay, C.; Middlemiss, D.; Mordaunt, J. E.; Pegg, N. A.; Vinader, M. V.; Ward, P.; Watson, S. P. Bioorg. Med. Chem. Lett. 1996, 6, 1015-1020.
22. (a) Hipskind, P. A.; Howbert, J. J.; Bruns, R. F.; Cho, S. S. Y.; Crowell, T. A.; Foreman, M. M.; Gehlert, D. R.; Iyengar, S.; Johnson, K. W.; Krushinski, J. H.; Li, D. L.; Lobb, K. L.; Mason, N. R.; Muehl, B. S.; Nixon, J. A.; Phebus, L. A.; Regoli, D.; Simmons, R. M.; Threlkeld, P. G.; Waters, D. C.; Gitter, B. D. 3-Aryl-1,2-diacetamidopropane Derivatives as Novel and Potent NK-1 Receptor Antagonists. J. Med. Chem. 1996, 39, 736-748.
23. (b) Gitter, B. D.; Bruns, R. F.; Howbert, J.; Waters, D. C.; Threlkeld, P. G.; Cox, L. M.; Nixon, J. A.; Lobb, K. L.; Mason, N. R.; Stengel, P. W.; Cockerham, S. L.; Silbaugh, S. A.; Gehlert, D. R.; Schober, D. A.; Iyengar, S.; Calligaro, D. O.; Regoli, D.; Hipskind, P. A. Pharmacological Characterization of LY3038-70: A Novel, Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 275, 737-744.
24. Ladduwahetty, T.; Baker, R.; Cascieri, M. A.; Chabers, M. S.; Haworth, K.; Keown, L. E.; MacIntyre, D. E.; Metzger, J. M.; Owen, S.; Rycroft, W.; Sadowski, S.; Seward, E. M.; Shepheard, S. L.; Swain, C. J.; Tattersall, F. D.; Watt, A. P.; Williamson, D. W.; Hargreaves, R. J. N-Heteroaryl-2-phenyl-3-(benzyloxy)-piperidines: A Novel Class of Potent Orally Active Human NK1 Antagonist. J. Med. Chem. 1996, 39, 2907-2914.
25. Hale, J. J.; Mills, S. G.; MacCoss, M. M.; Shah, S. K.; Qi, H.; Mathre, D. J.; Cascieri, M. A.; Sadowski, S.; Strader, C. D.; MacIntyre, D. E.; Metzger, J. M. 2-(S)-((3,5-Bis(trifluoromethyl)-benzyl)-oxy)-3-(S)-phenyl-4-((3-oxo-1,2,4- triazol-5-yl)methl)morpholine (1): A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist. J. Med. Chem. 1996, 39, 1760-1762.
26. (a) Kramer, M. S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J. J.; Reines, S. A.; Liu, G.; Snavely, D.; W.-Knowles, E.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Swain, C. J.; Harrison, T.; Hill, R. G.; Hefti, F.; Scolnick, E. M.; Cascieri, M. A.; Chicchi, G. G.; Sadowski, S.; Williams, A. R.; Hewson, L.; Smith, D.; Carlson, E. J.; Hargreaves, R. J.; Rupniak, N. M. J. Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors. Science 1998, 281, 1640-1645.
27. (b) Hale, J. J.; Mills, S. G.; MacCoss, M.; Finke, P. E.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Chicchi, G. G.; Kurtz, M.; Metzger, J. M.; Eiermann, G.; Tsou, N. N.; Tattersall, F. D.; Rupniak, N. M. J.; Williams, A. R.; Rycroft, W.; Hargreaves, R.; MacIntyre, D. E. Structural Optimization Affording 2-(R)-(1(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3- oxo-1,2,4-triazol-5-yl)methlmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist. J. Med. Chem. 1998, 41, 4607-4614.
28. (a) Natsugari, H.; Ikeura, Y.; Kiyota, Y.; Ishichi, Y.; Ishimaru, T.; Saga, O.; Shirafuji, H.; Tanaka, T.; Kamo, I.; Doi, T.; Otsuka, M. Novel, Potent, and Orally Active Substance P Anagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivaives of Pyrido[3,4-b]pyridine. J. Med. Chem. 1995, 38, 3106-3120.
29. 1 Receptor Antagonists: Synthesis and Antagonistic Activity of Various Heterocycles with an N-[3,5-Bis(trifluoromethyl)-benzyl]-N-methylcarbamoyl Substituent. Chem. Pharm. Bull. 1997, 45, 1642-1652.
30. 1 Receptor Antagonists: Determination of the Absolute Stereochemical Requirements. J. Med. Chem. 1998, 41, 4232-4239.
31. 1 receptor. Chem. Commun. 1998, 2141-2142.
32. The italic letter a before R and S denotes an axial chirality as suggested by Cahn et al.: Cahn, R. S.; Ingold, C.; Prelog, V. Specification of Molecular Chirality. Angew. Chem., Int. Ed. Engl. 1966, 5, 385-415.
33. +-NAD(P)H Models: Chirality Sink. Tetrahedron 1986,42, 961-973.
34. (b) Cuyegkeng, M. A.; Mannschreck, A. Liquid Chromatography on Triacetylcellulose, 14. Chromatographic Separation on Enantiomers and Barriers to Enantiomerization of Axially Chiral Aromatic Carboxamides. Chem. Ber. 1987, 120, 803-809.
35. (c) Thayumanavan, S.; Beak, P.; Curran, D. P. Asymmetric Deprotonation of N,N-Dihexyl-1-Naphthamides to Provide Atropisomers of N,N-Dihexyl-2-Alkyl-1-Naphthamides. Tetrahedron Lett. 1996, 37, 2899-2902.
36. (d) Clayden, J.; Westlund, N.; Wilson, F. X. Asymmetric Induction using Atropisomers: Diastereoselective Additions to 2-Acyl-1-Naphthamides. Tetrahedron Lett. 1996, 37, 5577-5580.
37. (e) Clayden, J. Stereocontrol with Rotationally Restricted Amides. Synlett 1998, 810-816.
38. Cascieri, M. A.; Ber, E.; Fong, T. N.; Sadowski, S.; Basal, A.; Swain, C.; Seward, E.; Frances, B.; Burns, D.; Strader, C. D. Characterization of the Binding of a Potent, Selective Radioiodonated Antagonist to the Human Neurokinin-1 Receptor. Mol. Pharmacol. 1992, 42, 458-463.
39. 1 Receptors. Eur. J. Pharmacol. 1991, 209, 277-279.
40. As for atropisomerism in 7-membered heterocycles, see: Gilman, N. W.; Rosen, P.; Earley, J. V.; Cook, C.; Todaro, L. J. Atropisomers of 1,4-Benzodiazepines. Synthesis and Resolution of a Diazepam-Related 1,4-Benzodiazepine. J. Am. Chem. Soc. 1990, 112, 3969-3978.
41. DAICEL Chemical Industries, Ltd., Japan.
42. The conversion of (αS,9R)-8b to (αR,9R)-8b is apparently faster than that from (αR,9R)-8b to (αS,9R)-8b. An accurate time course of conversion from (αR,9R)-8b to (αS,9R)-8b has not been estimated due to the small change (within a range of 2%).
43. 1 Antagonists: Conformationally Constrained Heterocyclic Bioisosters of the Ester Linkage. J. Med. Chem. 1995, 38, 923-933.
44. 1 Antagonists Derived from L-Tryptophan. J. Med. Chem. 1995, 38, 934-941.
45. Quirion, R.; Pilapil, C. Comparative Potencies of Substance P, Substance K, and Neuromedine K on Brain Substance P Receptors. Neuropeptides 1984, 4, 325-329.
46. 3H]Senktide. Neuropeptides 1991, 18, 107-114.
47. 1 Receptor Antagonists. Eur. J. Pharmacol. 1998, 341, 235-241.
48. 2+ channels.
49. (a) Maggi, C. A. The role of peptides in the regulation of the micturition reflex: an update. Gen. Pharmacol. 1991, 22, 1-24.
50. (b) Lecci, A.; Giuliani, S.; Garret, C.; Maggi, C. A. Evidence for a role of tachykinins as sensory transmitters in the activation of micturition reflex. Neuroscience 1993, 54, 827-837.
51. (a) Spearman, C. The proof and measurement of association between two things. Am. J. Psychol. 1904, 15, 72-101.
52. (b) Snedecor, G. W.; Cochran, W. G. Statistical Methods; The Iowa State University Press: Ames, IA, 1967.
53. (a) Mori, K. Revision of the Absolute Configuration of A-Factor. The Inducer of Stretomycin Biosynthesis, Basing on the Reconfirmed (R)-Configuration of (+)-Paraconic Acid. Tetrahedron 1983, 39, 3107-3109.
54. (b) Mattes, H.; Hamada, K.; Benezra, C. Stereospecificity in Allergic Contact Dermititis to Simple Substituted Methylene Lactone Derivatives. J. Med. Chem. 1987, 30, 1948-1951.
55. TEXSAN: Single-Crystal Structure Analysis Software, version 1.9; Molecular Structure Corp.: The Woodlands, TX, 1998.
56. Sheldrick, G. M. SHELXL93, Program for the Refinement of Crystal Structures; University of Göttingen: Germany, 1993.